Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
RIVARELTO (Accord Healthcare Pty Ltd)
Product name
RIVARELTO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
128 (255 working days)
Active ingredients
Rivaroxaban
Registration type
New generic medicine
Indication
RIVAROXABAN is indicated for:
- Prevention of venous thromboembolism (VTE) in adult patients who haveundergone major orthopaedic surgery of the lower limbs (elective total hipreplacement, treatment for up to 5 weeks; elective total knee replacement,treatment for up to 2 weeks)
- Prevention of stroke and systemic embolism in patients with non-valvular atrialfibrillation and at least one additional risk factor for stroke
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and forthe prevention of recurrent DVT and PE
RIVAROXABAN, in combination with aspirin, is indicated for:
- The prevention of major cardiovascular events (composite of stroke, myocardialinfarction and cardiovascular death) in patients with coronary artery disease(CAD) and/or peripheral artery disease (PAD)